Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis

Fibrosis is characterized by excessive accumulation of extracellular matrix components. The fibrotic process ultimately leads to organ dysfunction and failure in chronic inflammatory and metabolic diseases such as pulmonary fibrosis, advanced kidney disease, and liver cirrhosis. Idiopathic pulmonary...

Full description

Bibliographic Details
Main Authors: Suji Kim, Jae Hyang Lim, Chang-Hoon Woo
Format: Article
Language:English
Published: Yeungnam University College of Medicine 2020-10-01
Series:Yeungnam University Journal of Medicine
Subjects:
Online Access:http://www.e-yujm.org/upload/pdf/yujm-2020-00458.pdf
_version_ 1818040396569116672
author Suji Kim
Jae Hyang Lim
Chang-Hoon Woo
author_facet Suji Kim
Jae Hyang Lim
Chang-Hoon Woo
author_sort Suji Kim
collection DOAJ
description Fibrosis is characterized by excessive accumulation of extracellular matrix components. The fibrotic process ultimately leads to organ dysfunction and failure in chronic inflammatory and metabolic diseases such as pulmonary fibrosis, advanced kidney disease, and liver cirrhosis. Idiopathic pulmonary fibrosis (IPF) is a common form of progressive and chronic interstitial lung disease of unknown etiology. Pathophysiologically, the parenchyma of the lung alveoli, interstitium, and capillary endothelium becomes scarred and stiff, which makes breathing difficult because the lungs have to work harder to transfer oxygen and carbon dioxide between the alveolar space and bloodstream. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis and scarring of the lung tissue. Recent clinical trials focused on the development of pharmacological agents that either directly or indirectly target kinases for the treatment of IPF. Therefore, to develop therapeutic targets for pulmonary fibrosis, it is essential to understand the key factors involved in the pathogenesis of pulmonary fibrosis and the underlying signaling pathway. The objective of this review is to discuss the role of kinase signaling cascades in the regulation of either TGF-β-dependent or other signaling pathways, including Rho-associated coiled-coil kinase, c-jun N-terminal kinase, extracellular signal-regulated kinase 5, and p90 ribosomal S6 kinase pathways, and potential therapeutic targets in IPF.
first_indexed 2024-12-10T08:13:52Z
format Article
id doaj.art-ba19b8acbd704e6b86da1cf985dfbedb
institution Directory Open Access Journal
issn 2384-0293
language English
last_indexed 2024-12-10T08:13:52Z
publishDate 2020-10-01
publisher Yeungnam University College of Medicine
record_format Article
series Yeungnam University Journal of Medicine
spelling doaj.art-ba19b8acbd704e6b86da1cf985dfbedb2022-12-22T01:56:30ZengYeungnam University College of MedicineYeungnam University Journal of Medicine2384-02932020-10-0137426927610.12701/yujm.2020.004582503Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosisSuji Kim0Jae Hyang Lim1Chang-Hoon Woo2 Smart-Ageing Convergence Research Center, Yeungnam University College of Medicine, Daegu, Korea Department of Microbiology, Ewha Womans University College of Medicine, Seoul, Korea Smart-Ageing Convergence Research Center, Yeungnam University College of Medicine, Daegu, KoreaFibrosis is characterized by excessive accumulation of extracellular matrix components. The fibrotic process ultimately leads to organ dysfunction and failure in chronic inflammatory and metabolic diseases such as pulmonary fibrosis, advanced kidney disease, and liver cirrhosis. Idiopathic pulmonary fibrosis (IPF) is a common form of progressive and chronic interstitial lung disease of unknown etiology. Pathophysiologically, the parenchyma of the lung alveoli, interstitium, and capillary endothelium becomes scarred and stiff, which makes breathing difficult because the lungs have to work harder to transfer oxygen and carbon dioxide between the alveolar space and bloodstream. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in the pathogenesis of pulmonary fibrosis and scarring of the lung tissue. Recent clinical trials focused on the development of pharmacological agents that either directly or indirectly target kinases for the treatment of IPF. Therefore, to develop therapeutic targets for pulmonary fibrosis, it is essential to understand the key factors involved in the pathogenesis of pulmonary fibrosis and the underlying signaling pathway. The objective of this review is to discuss the role of kinase signaling cascades in the regulation of either TGF-β-dependent or other signaling pathways, including Rho-associated coiled-coil kinase, c-jun N-terminal kinase, extracellular signal-regulated kinase 5, and p90 ribosomal S6 kinase pathways, and potential therapeutic targets in IPF.http://www.e-yujm.org/upload/pdf/yujm-2020-00458.pdffibrosisidiopathic pulmonary fibrosiskinasetransforming growth factor beta
spellingShingle Suji Kim
Jae Hyang Lim
Chang-Hoon Woo
Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
Yeungnam University Journal of Medicine
fibrosis
idiopathic pulmonary fibrosis
kinase
transforming growth factor beta
title Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
title_full Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
title_fullStr Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
title_full_unstemmed Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
title_short Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
title_sort therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
topic fibrosis
idiopathic pulmonary fibrosis
kinase
transforming growth factor beta
url http://www.e-yujm.org/upload/pdf/yujm-2020-00458.pdf
work_keys_str_mv AT sujikim therapeuticpotentialoftargetingkinaseinhibitioninpatientswithidiopathicpulmonaryfibrosis
AT jaehyanglim therapeuticpotentialoftargetingkinaseinhibitioninpatientswithidiopathicpulmonaryfibrosis
AT changhoonwoo therapeuticpotentialoftargetingkinaseinhibitioninpatientswithidiopathicpulmonaryfibrosis